At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Ivermectin (IVM)drug
Likely dose
Ivermectin (IVM) 0.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial)
In Brief
A Phase 1 clinical trial evaluating Ivermectin (IVM) for COVID 19. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID 19
CountriesIraq
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartApr 2020
Primary CompletionMay 2020
Study CompletionJun 2020
TodayJul 2026
First PostedApr 13, 2020
Enrollment StartApr 18, 2020
Primary CompletionMay 31, 2020
Study CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.2 years ago
Interventions
Ivermectin (IVM)drug
Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly